Standard BioTools Regains Nasdaq Bid Price Compliance
LAB sits 32% above its 52-week low of $0.87.
Summary
Standard BioTools Inc. has announced it has regained compliance with Nasdaq's minimum bid price rule, resolving the previously reported delisting concern.
Key Events · Corporate Governance and Compliance · LAB
-
Regains Nasdaq Compliance
The company received a letter from Nasdaq confirming it has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)).
-
Delisting Threat Removed
This resolves the previously reported non-compliance notice received on April 20, 2026, and removes the risk of delisting from the Nasdaq Global Select Market.
Analysis · LAB · Industrial Applications And Services
This 8-K announces that Standard BioTools has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the previously disclosed delisting threat. This resolution is a positive development for investor confidence and ensures the company's continued listing on the Nasdaq Global Select Market.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.4% of the 908 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.9M. The 52-week trading range was $0.87 to $1.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.